The Impact of MicroLactin® It has been tested numerous times on various animals. Below are various independent studies that have proven MicroLactin's effectiveness.® among other things, improving joint function, overall fitness and demonstrating anti-inflammatory effects.
The double-blind, placebo-controlled study involved large dogs aged 7–12 years with symptoms of joint degeneration. After 8 weeks of MicroLactin supplementation,® , 67% dogs showed significant improvement – confirmed by both owners and veterinarians1.
Studies conducted on 28 horses with advanced neurological symptoms (EPM - protozoal encephalomyelitis) - the animals were no longer suitable for further work as riding or sport horses - showed that the use of therapy containing MicroLactin® as an anti-inflammatory ingredient, it significantly increases the effectiveness of treatment.
After a month of therapy:
In comparison, standard antiprotozoal treatment only brings:
The better results were attributed to the presence of MicroLactin® , which has a strong anti-inflammatory effect and supports the regeneration of the nervous system2.
Another study included horses aged 1 to 36 years suffering from various inflammatory conditions. After using MicroLactin® 88% horses showed a significant improvement – reduced pain, stiffness and other symptoms of inflammation3.
Publications:
Discover why MicroLactin® It's more than just a supplement. Find out how it works, where it comes from, and why it's a safe choice for your pet.
References confirming the effectiveness of MicroLactin®:
1 Tizard, I. Adaptive immunity. Merck Veterinary Manual Web site. Accessed July 2, 2017. Available at http://www. merckvetmanual.com/immune-system/the-biology-of-the-immune-system/adaptive-immunity.
2 Edwards, S. H. Chemical mediators of inflammation. Merck Veterinary Manual Web site. Accessed July 2, 2017. Available at http://www.merckvetmanual.com/pharmacology/anti-inflammatory-agents/chemical-mediators-of-inflammation.
3 Muller WA. Getting leukocytes to the site of inflammation. Veterinary Pathology. 2013; 50(1): 7-22. Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628536/
4 Beck LR, Fuhrer JP. Milk lymphocyte anti-adhesion factor, and its role as an anti-microbial. International Dairy Federation. 1993; 62-72.
5 Allen J, Hector D. Benefits of breastfeeding. New South Wales Public Health Bulletin. 2005; 16: 42-46.
6 Beck LR, Fuhrer JP. Anti-inflammatory factor, method of isolation, and use. US Patent #5980953. Nov 1999.
7 Wilborn WH, Hyde BM, Beck LR, Fuhrer JP. Milk from hyperimmunized cows stimulates lysosomal activity in rat lung macrophages. Summary of presentation at The Lovelace Respiratory Research Institute Symposium on Respiratory Immunology; Santa Fe, NM. 1999.
8 Gingerich DA, Strobel JD. Use of client-specific outcome measures to assess treatment effects in geriatric, arthritic dogs: controlled clinical evaluation of a nutraceutical. Veterinary Therapeutics. 2003; 4(1): 56-66.
9 Bello TR, Allen TA. The use of MicroLactin for inflammatory conditions in equine veterinary practice. Journal of Equine Veterinary Science. 2005; 25(9): 380-382.
10 Bello TR, Allen TM. An intensive approach in the treatment of clinical equine protozoal myeloencephalitis. Journal of Equine Veterinary Science. 2008; 28(8): 479-483.
11 MacKay RJ. Equine protozoal myeloencephalitis: treatment, prognosis, and prevention. Clin Tech Equine Pract. 2006; 5: 9-16.
12 Ormrod DJ, Miller TE. The anti-inflammatory activity of a low molecular weight component derived from the milk of hyperimmunized cows. Agents and Actions. 1991; 32(3/4): 160-166.
13 Ormrod DJ, Miller TE. A low molecular weight component derived from the milk of hyperimmunized cows suppresses inflammation by inhibiting neutrophil emigration. Agents and Actions. 1992; 37: 70-79.
14 Beck LR. Method of treating inflammation using bovine milk. US Patent #4284623. Aug 1981.
15 Ormrod DJ, Miller TE. Milk from hyperimmunized dairy cows as a source of a novel biological response modifier. Agents and Actions. 1993; 38(Special Conference Issue): C146-C149.
16 Woodman R, Fuhrer P, Beck L, Kubes P. The effects of hyperimmune milk factor (HIMF) on neutrophil adhesion in vivo [Abstract]. Society for Leukocyte Biology, 29th National Meeting, Charleston South Carolina. 1992.
17 Sonoda S, Spee C, Barron E, Ryan SJ, Kannan R, Hinton DR. A protocol for the culture and differentiation of highly polarized human retinal pigment epithelial cells. Nature protocols. 2009; 4(5): 662-673.
18 Stelwagen K, Ormrod DJ. An anti-inflammatory component derived from milk of hyperimmunized cows reduces tight junction permeability in vitro. Inflammation Research. 1998; 47: 384-388.
19 Owens WE, Nickerson SC, Washburn PJ. Effect of a milk-derived factor on the inflammatory response to Staphylococcus aureus intramammary infection. Veterinary Immunology and Immunopathology. 1992; 30: 233-246.
20 Rosloniec EF, Cremer M, Kang AH, Myers LK, Brand DD. Collagen-induced arthritis. Curr Protoc Immunol. Apr 2010; Chapter 15: Unit 15.5.1-25.
21 Gingerich DA, Strobel JD, Brown A, Fuhrer JP. Efficacy of SMBI milk bioactive factors in a collagen-induced arthritis model in mice. Summary of presentation at Japan Rheumatism Association; Tokyo, Japan. 1997.
22 Stolle RJ, Beck LR. Prevention and treatment of rheumatoid arthritis. US Patent #4732757A. 1991.
23 Beck LR, Ishida A, Yoshikai Y, Murosaki S, Kubo C, Hidaka Y, Nomoto K. Use of hyperimmune milk to prevent suppression of T-lymphocyte production. US Patent #6056978. May 2000.
